Business Update; Impact of pharmaceutical companies' shifting clinical outsourcing analyzed

In an effort to reduce the cost and time spent conducting clinical trials, pharmaceutical companies like Wyeth and Pfizer are overhauling their relationships with CROs and forcing significant change in the clinical outsourcing market. According to Life Science Insights (LSI), shifting sponsor sentiment towards alternative sourcing approaches represents a call to action for CROs offering end-to-end contract research services. In the newly released study, "Clinical Outsourcing Sponsors Force Market Change" (doc #1013), LSI examines the outsourcing preferences of a variety of surveyed pharmaceutical organizations and finds that many are backing away from end-to-end, full-service contracts with CROs (despite the positioning of large CROs), instead selecting providers based on their capabilities in distinct service and technology categories. A matrix featured in the report reflects selected examples of leading providers and service capabilities along the clinical outsourcing services continuum. Life Science Insights, an IDC company, provides market research, analysis and consulting services to decision makers in life science markets. This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2005, Life Science Weekly via NewsRx.com.

Source: Life Science Weekly

For more information, please contact:
Howard Sholkin
howard_sholkin@idg.com
617-239-7882